Details for Patent: 10,975,046
✉ Email this page to a colleague
Which drugs does patent 10,975,046 protect, and when does it expire?
Patent 10,975,046 protects BYLVAY and is included in one NDA.
This patent has forty patent family members in twenty countries.
Summary for Patent: 10,975,046
| Title: | Crystal modifications of odevixibat |
| Abstract: | The present invention relates to crystal modifications of 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N--{(R)-.alpha.-[N--((S)-1- -carboxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrah- ydro-1,2,5-benzothiadiazepine (odevixibat), more specifically crystal modifications 1 and 2 of odevixibat. The invention also relates to a process for the preparation of crystal modification 1 of odevixibat, to a pharmaceutical composition comprising crystal modification 1, and to the use of this crystal modification in the treatment of various conditions as described herein. |
| Inventor(s): | Lundqvist; Robert (Halso, SE), Ymen; Ingvar (Saltsjo-Boo, SE), Bohlin; Martin (Johanneshov, SE), Byrod; Eva (Molndal, SE), Gillberg; Per-Goran (Molndal, SE), Tivert; Anna-Maria (Gothenburg, SE), Bryland; Rikard (Limhamn, SE), Dahlquist; Ann-Charlotte (Lund, SE), Elversson; Jessica (Dalby, SE), Gustafsson; Nils Ove (Loddekopinge, SE) |
| Assignee: | Albireo AB (Gothenburg, SE) |
| Application Number: | 16/508,036 |
|
Patent Claim Types: see list of patent claims | Compound; Process; |
Drugs Protected by US Patent 10,975,046
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ipsen | BYLVAY | odevixibat | CAPSULE, PELLETS;ORAL | 215498-001 | Jul 20, 2021 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Ipsen | BYLVAY | odevixibat | CAPSULE, PELLETS;ORAL | 215498-003 | Jul 20, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Ipsen | BYLVAY | odevixibat | CAPSULE;ORAL | 215498-002 | Jul 20, 2021 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Ipsen | BYLVAY | odevixibat | CAPSULE;ORAL | 215498-004 | Jul 20, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 10,975,046
International Family Members for US Patent 10,975,046
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2019290337 | ⤷ Try a Trial | |||
| Australia | 2019290338 | ⤷ Try a Trial | |||
| Brazil | 112020024461 | ⤷ Try a Trial | |||
| Brazil | 112020024479 | ⤷ Try a Trial | |||
| Canada | 3100687 | ⤷ Try a Trial | |||
| Canada | 3100691 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
